NASDAQ: DNTH

Dianthus Therapeutics (DNTH) Stock Analysis & Forecast

Nov 13 close

$91.81−0.67 (−0.7%)

Gekko Brief

AI summaryNov 9 close

Dianthus Therapeutics reported third-quarter 2026 results on 4 November, posting a loss that beat revenue estimates and compared to a loss of $0.97 per share a year ago. The company highlighted progress on its neuromuscular franchise, including claseprubart, which is in Phase 3 EMERGE trials across generalized Myasthenia Gravis, CIDP and MMN. Separately, Dianthus announced inducement grants for newly-hired employees and confirmed participation in five investor conferences during November, while an officer filed notice of a proposed sale of 124,042 shares valued at $10.67 million.

DNTH closed at $90.00, up 4.6%, sitting above both its 50-day average of $89.73 and 200-day average of $86.14, with the 50-day above the 200-day. The GekkoIndex reads 53.3, placing the stock in the Neutral zone, down 6.4 points over five sessions. Price remains 17.6% below Gekko Fair Value of $109.27, a gap wider than the typical 5% threshold watched for valuation extremes.

The next earnings date falls on 8 March 2027, 118 days out, outside the typical 20-trading-day holding window. Smart money readings show no insider, Congress, or unusual options activity in their respective 90-day and 30-day windows. Seasonality is a headwind: over five years, the next 20 trading days from this point averaged a -7.9% return, rising in just 1 of those years. Consensus among 10 analysts remains all-buy, with a target of $139.06 implying 54.5% upside.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Dianthus Therapeutics price vs fair value

$108.71$91.81Nov ’25May ’26Nov ’26
Close $91.81200-day averageGekko Fair Value $108.71

Dianthus Therapeutics quick facts

Market cap
$5.17B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$4.23
Revenue, TTM
$2.72M
Profit margin
0%
Dividend yield
—
Beta
0.26
Volume
681,514 avg 918,602
1-year return
+137.1%
Typical daily move
±4.9%
Typical 20-day move
±11.4%
50-day average
$88.45
200-day average
$86.93
Next earnings
Mar 8
Shares outstanding
56.31M
52-week range
$34.29$117.88

Dianthus Therapeutics swing-trade checklist

Dianthus Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $91.81 is above the 50-day ($88.45) and 200-day ($86.93) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    50.4, Neutral

    Reading 50.4 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    15.5% below

    Price is 15.5% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 113 days

    Next report Mar 8, 2027, 113 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −20.6% on average

    From this point in the calendar, the next 20 trading days averaged −20.6% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Dianthus Therapeutics stock chart and price history

Dianthus Therapeutics closed at $91.81 on Nov 13, 2026, +137.1% over the past year, inside a 52-week range of $34.29 to $117.88.

Close50-day average200-day averageVolume
Dianthus Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$20$40$60$80$100$120DecJan 2026FebMarAprMayJunJulAugSepOctNov91.81

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+23.2%
3 months
−20.1%
6 months
+6.6%
1 year
+137.1%
The full DNTH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DNTH in Gekko

Follow Dianthus Therapeutics through every session

Put DNTH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track DNTH in GekkoFree for 7 days. No credit card required.

About Dianthus Therapeutics

Dianthus Therapeutics works on medicines for people with serious autoimmune conditions, operating as a clinical-stage biotechnology company. Its furthest-along candidate, claseprubart, is a monoclonal antibody built for a longer half-life, stronger potency, and narrow targeting of only the active form of the C1s complement protein. It is best known for this program among its pipeline of experimental treatments.

The company also has a second candidate, DNTH212, described as a bifunctional fusion protein. This molecule is designed to act on plasmacytoid dendritic cells through BDCA2 to lower Type 1 interferon output, while at the same time blocking BAFF and APRIL to limit B cell activity. As a clinical-stage business, Dianthus Therapeutics centers its work on advancing these drug candidates through development rather than on selling approved products.

Dianthus Therapeutics was established in 2019 and has its headquarters in New York, New York. Its shares are listed on the NASDAQ under the ticker DNTH.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
dianthustx.com

Dianthus Therapeutics GekkoIndex: the smart money zone

Dianthus Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.4, in the Neutral zone, down 6.2 points over five sessions.

010050.4Neutral

Down 6.2 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying31+6.2%+9.7%+12.7%+54.9%
Accumulation188+2.5%+4.8%+8.0%+16.7%
Neutral (current zone)425+0.8%+1.8%+4.2%+13.2%
Distribution41+3.6%+3.7%+8.3%+15.7%
Selling17+9.6%+16.0%+22.4%+27.3%

Average DNTH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the DNTH price, zone by zone.Track DNTH in Gekko

Is Dianthus Therapeutics stock overvalued? Gekko Fair Value

Dianthus Therapeutics trades 15.5% below Gekko Fair Value of $108.71, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Dianthus Therapeutics shares are worth, recalculated every trading day.

$108.71

Gekko Fair Value, Nov 14, 2026

15.5% Undervalued

At the end of Aug 2026 the price was 16.0% below the estimate.

Gekko Fair ValueShare price, month end
$109$92Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open DNTH in Gekko

Dianthus Therapeutics insider and Congress trading

No open-market insider purchases were filed for Dianthus Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for DNTH in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every DNTH insider filing, plotted on the chart in Gekko.Open DNTH in Gekko

Congress trades last 90 days

No trades in DNTH were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for DNTH, plotted on the chart in Gekko.Open DNTH in Gekko

Buybacks

Dianthus Therapeutics has been buying back its own shares.

Bought back, quarter ended Dec 31, 2025
$317K
As a share of market cap
0.01%

From company filings.

Dianthus Therapeutics earnings: next date and track record

Dianthus Therapeutics reports on Mar 8, 2027 (113 days away), and beat the EPS estimate in 1 of its last 8 reports.

1 of 8reports beat the EPS estimate
±9.8%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+6.6%Aug ’24−1.2%Nov ’24−10.0%Mar ’25−3.8%May ’25−8.0%Aug ’25+9.7%Nov ’25+33.3%Mar ’26+6.1%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 4, 2026−$0.90
est −$0.85
−6.3%$761K
est $297K
+156.1%+6.1%
Mar 9, 2026−$1.43
est −$0.98
−45.9%$284K
est $552K
−48.6%+33.3%
Nov 5, 2025−$0.97
est −$0.86
−12.8%$396K
est $398K
−0.5%+9.7%
Aug 7, 2025−$0.88
est −$0.86
−2.3%$193K
est $865K
−77.7%−8.0%
May 12, 2025−$0.82
est −$0.71
−15.5%$1.16M
est $807K
+44.1%−3.8%
Mar 11, 2025−$0.81
est −$0.76
−6.6%$1.33M
est $955K
+38.7%−10.0%
Nov 7, 2024−$0.72
est −$0.59
−22.0%$2.17M
est $844K
+157.3%−1.2%
Aug 8, 2024−$0.51
est −$0.55
+7.3%$1.86M
est $320K
+482.2%+6.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Dianthus Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Dianthus Therapeutics is $139.25, +51.7% from the last close, from 10 firms rating the stock in the last 90 days.

$139.25consensus 12-month target, +51.7% from the last close
Low $113High $200
Buy10
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 10 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Stifel NicolausBuy, maintained$133+44.9%
Nov 6H.C. WainwrightBuy, maintained$158+72.1%
Nov 5Wells FargoBuy, maintained$135+47.0%
Nov 5Stifel NicolausBuy, reiterated$133+44.9%
Nov 5WedbushBuy, maintained$122+32.9%
+4.2%average 20-day move after past Neutral readings
−20.6%average move over the next 20 trading days in the last 5 years
±4.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Dianthus Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Dianthus Therapeutics averaged −20.6% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−33.5%2021−31.2%2022−30.2%2023−6.6%2024+2.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−9.2%2 of 5
Next 10 trading days−11.0%2 of 5
Next 15 trading days−12.2%1 of 5
Next 20 trading days−20.6%1 of 5
Next 30 trading days−27.5%1 of 5

For scale, DNTH’s typical 20-trading-day move in either direction is about 11.4%.

Dianthus Therapeutics market cap and key statistics

Dianthus Therapeutics’s market cap is $5.17B and revenue of $2.72M over the last twelve months.

Valuation

Market cap
$5.17B
EPS, TTM
−$4.23
Gekko Fair Value
$108.71

Trading

Volume
681,514
Avg volume, 20 days
918,602
52-week high
$117.88
52-week low
$34.29
Shares outstanding
56.31M

Financials

Revenue, TTM
$2.72M
Profit margin
0%
Return on equity
-22.6%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.26
Typical daily move
±4.9%
Typical 20-day move
±11.4%

Dianthus Therapeutics peers

Dianthus Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Dianthus Therapeutics stock FAQ

What is Dianthus Therapeutics’s market cap?

Dianthus Therapeutics’s market cap is $5.17B at the Nov 13, 2026 close of $91.81, with 56.31M shares outstanding.

What is the Dianthus Therapeutics stock forecast?

The consensus analyst 12-month price target for Dianthus Therapeutics is $139.25, +51.7% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Dianthus Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Dianthus Therapeutics is undervalued: the Nov 13, 2026 close of $91.81 is 15.5% below Gekko Fair Value of $108.71. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Dianthus Therapeutics report earnings next?

Dianthus Therapeutics is expected to report on Mar 8, 2027 (113 days away). Analysts expect earnings of −$0.96 per share on revenue of $448K. Dianthus Therapeutics beat the earnings estimate in 1 of its last 8 reports, moving 9.8% on average across the report.

What is Dianthus Therapeutics’s 52-week high and low?

Dianthus Therapeutics’s 52-week high is $117.88 and its 52-week low is $34.29; it closed at $91.81 on Nov 13, 2026, +137.1% over the past year. Over the last five years the shares peaked at $122.08 on Nov 15, 2021.

Is Dianthus Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Dianthus Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.